Navigation Links
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
Date:6/13/2008

Data Presented at the European Cystic Fibrosis Society Conference

MONMOUTH JUNCTION, N.J., June 13 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial on its lead investigational drug, Arikace(TM) (liposomal amikacin for inhalation). The compound is being developed for the treatment of cystic fibrosis (CF) patients who have lung infections due to the bacterium Pseudomonas aeruginosa. The Phase II data indicated that Arikace, delivered once daily for 28 consecutive days, produced a significant improvement in lung function, was well-tolerated, and had a side-effect profile comparable to placebo. The Phase II trial was a randomized, double-blind, placebo-controlled study of 64 patients from 15 centers in Europe. Results were presented today at the 31st European Cystic Fibrosis Society (ECFS) Conference in Prague, Czech Republic, by Lieven Dupont, MD, Associate Professor of Respiratory Medicine at the Katholieke Universiteit, Leuven, Belgium, and co-lead investigator of the study.

Arikace is a novel molecular entity comprised of the antibiotic amikacin, which is enclosed in nanocapsules of lipids called liposomes. Arikace was administered once daily for 28 days at 280 mg and 560 mg dosages, using a novel inhalation device, the eFlow(R) Electronic Nebulizer (PARI Pharma GmbH).

The intent-to-treat analysis for efficacy demonstrated that Arikace, when administered once daily either at 280 mg or 560 mg for 28 days, resulted in clinically significant improvement in lung function at the end of treatment. This improvement was dose-dependent and was sustained at 28 days after completion of dosing, which was day 56 of the study. Pulmonary function (FEV1) increased significantly among patients receiving the 560 mg dose of Arikace, with a sustained treatment effect of 224 ml (p=0.004) and 17.6% (p=0.009) increase compared to placebo, at day 56.

Arikace was well tolerated, with no differences observed in
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
2. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
3. XTENT Announces European Regulatory Update
4. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
5. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
6. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
7. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
8. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
9. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
10. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
11. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
(Date:1/22/2015)...  ResMed Inc. (NYSE: RMD ) today announced results ... quarter was $423.0 million, a 10 percent increase compared to ... on a constant currency basis). Net income was $91.2 million, ... December 31, 2013. Diluted earnings per share for the quarter ...
(Date:1/22/2015)... 22, 2015 Increasing sophistication among enterprise buyers of ... purchasing in 2015, says Moravia CMO, ... study by market research firm Common Sense Advisory, 15 ... their translation and localization needs. "From a language industry ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... DIEGO , March 16 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) today reported financial results for the fourth quarter and year ended December 31, 2009 . ... , ... ... ...
... Sigma-Aldrich® (Nasdaq: SIAL ) today announced ... Inc., a Berks County, PA. -based provider of ... Animals ( www.aceanimals.com ), a commercial rodent breeder established ... services, and will operate as part of Sigma Advanced ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 7ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 8ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 9ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 10ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results 11Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7
(Date:1/22/2015)... The federal court overseeing thousands of vaginal mesh ... District of West Virginia has upheld a $2 million verdict ... trial. In an Order dated January 21st, the Court denied ... C.R. Bard had not proven a miscarriage of justice. (Cisson ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... January 22, 2015 State Forestry Institute ... management system with support from GEOSYSTEMS, a dedicated Hexagon ... solution will leverage Hexagon Geospatial’s ERDAS APOLLO ... as well as point clouds and documents. This effort ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... ... feature that allows project managers to find out about changes across multiple projects in ... ... a leader in online project management software innovations, sets a new project ...
... to return to normal state of alertness , WEDNESDAY, June ... of having to start the day without a cup of ... way. , Regular coffee drinkers seem to need caffeine to ... the side effects of caffeine withdrawal such as headaches. That ...
... Minority organ donations have more than doubled since the ... new retrospective study published in the May issue of the ... 2010, the percentage of minority donors is expected to reach ... Since the first organ transplant in 1954, the shortage of ...
... are reporting development of the first "dipstick" test for instantly ... a few pennies. Their study on the test, which involves ... strip, appears in ACS, semi-monthly journal Analytical Chemistry , ... health care in developing countries. The test also could be ...
... After years of research and anticipation, insulin pills that could ... diabetes are finally moving ahead in clinical trials and a ... in a two-part cover story on drug manufacturing in the ... C&EN ), ACS, weekly newsmagazine. C&EN ...
... -- Cancer-related fatigue is often a major problem ... and after completing therapy. Researchers at Mayo Clinic ... Treatment Group ( http://ncctg.mayo.edu/ ) (NCCTG) recently completed ... cancer-related fatigue and found that, while it did ...
Cached Medicine News:Health News:Wrike Introduces a Game-Changing Microblogging Tool for Project Managers 2Health News:Coffee's Jolt Just an Illusion? 2Health News:Coffee's Jolt Just an Illusion? 3Health News:Grassroots programs to encourage minority organ donation prove successful 2Health News:Results from a study testing methylphenidate for cancer-related fatigue 2Health News:Results from a study testing methylphenidate for cancer-related fatigue 3
Richardson Retractors...
A full, rounded look that adds greater dimension to the breast. Moderate base, with a higher profile than our Style 1600 implant....
Inquire...
... Anatomically designed to enhance the chin contour, this ... with a high-profile central chin projection. Symmetrical ... mandible, this implant provides a high central projection, ... Cleft Chin Implants - Designed with a ...
Medicine Products: